



ASSOCIATION OF STATE AND  
TERRITORIAL HEALTH OFFICIALS


**ASTHO Survey of State and Territorial Pandemic Influenza Antiviral Purchase and Stockpiling  
October 2006**

In October 2006, ASTHO conducted a survey of the states and territories to provide a point-in-time picture of the states' antiviral purchasing and stockpiling activities and plans. This survey is a follow-up to a survey that was conducted in April 2006, the results from which are available on ASTHO's web site. ASTHO received a total of 54 responses from 50 states, the District of Columbia, and 3 territories. State and territorial responses reflect activities as of October 1, 2006.


**ANTIVIRAL PURCHASE**

**At this time, does your state have antivirals in its stockpile?**

- Of 54 states that responded to this question, 13 (24% of respondents) answered that they have antivirals in their state stockpile. Forty-one states (76% of respondents) do not.




**Thirteen states reported antivirals in their state stockpile in the following quantities:**



- The number of reported stockpiled antiviral courses from 13 states ranged from 200 courses to 1,056,072 courses, and totaled 1,317,824 courses.

**As of October 1, 2006, which of the following best describes your state’s current thinking with regard to antiviral purchasing?**




- Between August and October 2006, five states decided to reconsider their participation in the federal subsidy.
- As of October 1, 2006, 43 states (81% of respondents) are participating or will participate in the federal subsidy program.

■ Reported to HHS as of August 1, 2006 (52 total respondents)  
 ■ Current thinking as of October 1, 2006 (53 total respondents)


- Ten states (19% of respondents) responded with “other.” Additional comments provided by “other” respondents indicated that six states would participate pending the availability of funding, legislative approval, or appropriations. Two of these states were in discussions with their Governors’ offices, while one state made recommendations for a state purchase, but funds were not appropriated.
- At the time of this survey, states were still awaiting inventory management information from the federal government on the possible eligibility of state antiviral purchases for the FDA’s Shelf Life Extension Program and/or CDC’s Strategic National Stockpile. Two states that responded “Other” is considering plans to purchase antivirals directly from the manufacturers so that they have the option to rotate stock within their state.

**What is the quantity of treatment course purchases through the federal subsidy program that is being contemplated by your state?**




- Of the 51 state responses received, 33 (65% of respondents) states are planning to purchase the full amount allotted through the federal subsidy program. Seven (14% of respondents) states will purchase in excess of their federal allotment should supplies become available, and ten states (20% of respondents) will purchase less than their federal allotment. One state reported that they do not plan to purchase antivirals through the federal plan, but will purchase their antivirals directly from manufacturers.

**As of October 1, 2006, what is the total number of treatment courses that has been ordered under the federal contracts?**




- Of the 51 state responses received, 28 states (55% of respondents) had not ordered antiviral treatment courses under the federal contracts.
- Ten states (20% of respondents) had ordered less than 100,000 treatment courses.
- The number of treatment courses ordered ranged from 0 to 3,700,000 courses, and totaled 9,113,935 courses.

**As of October 1, 2006, have state funds been identified and put in place for antiviral purchase?**




- Of the 54 state respondents, 25 states (46% of states) have identified and put in place state funds for antiviral purchase. Twenty-nine states (54% of states) have not.
- HHS has mandated that all eligible entities respond in writing to HHS by December 29, 2006 to provide a formal purchase plan for their respective subsidized antiviral orders to be placed in the subsequent 18 months remaining of the federal subsidy program.

- Of the 25 states that reported having identified state funds for antiviral purchase, actual dollar amounts ranged from \$100,000 to \$54,648,000.
- Two states that have already procured \$1 million to \$1.6 million, are seeking additional state funding for more antivirals.




**What mechanisms are being pursued to fund your state’s share of the procurement?**



- Twenty-nine states reported pursuing emergency and/or special supplemental appropriations from their state legislature. The amount of appropriations reported ranged from \$363,340 to \$15,669,072.
- Five states reported that they would utilize existing funds in their Agency’s state operating budgets. The amount of money reported ranged from \$280,000 to \$157 million. Twenty states reported utilizing funds that were or will be part of the routine annual budget process with amounts ranging from \$50,500 to \$54,648,000.
- Eighteen states plan to utilize federal funding subject to availability and federal agency approval, such as HRSA and DHS grant funding, and of the nine responses that reported “other,” three states have yet to determine funding mechanisms.
- Seventeen states reported that they plan on sharing costs with other entities within their states, ranging from \$44,800 to \$6.5 million.


**States have 24 months to order and pay for their antiviral purchase under the federal antiviral contracts. In light of this timeline, within how many state fiscal years does your state plan to make its total antiviral purchase?**



- Of 52 respondents, 30 (58% of respondents) states plan to complete their total antiviral purchase in 2 years.
- Nineteen states (37%) will make their antiviral purchase in 1 year.



**If your state is cost-sharing with other entities within the state to finance the antiviral purchase, with which entities is your state health agency partnering?**

- For states that responded with “other,” entities that states are partnering with include other state/local government agencies, long term care facilities, health care centers, the State Guard, other first responder organizations, and business entities.



**INVENTORY MANAGEMENT**

**In lieu of using the Strategic National Stockpile and the Shelf Life Extension Program for state purchased antivirals, has your state identified and secured a location or mechanism to store and manage the purchased antivirals upon delivery?**



- Of the 54 states that responded to this question, 35 states (65% of respondents) have identified a mechanism to store and manage their antiviral stockpile.
- Many states reported that they will store and manage their own antiviral stockpile. Those who responded with “other” reported storage with local health departments and hospitals.

**Has your state attempted to quantify how much it would cost to store and manage the purchased state stockpile?**

- Of 53 state responses received, 36 states (68% of respondents) had not attempted to quantify how much it would cost to store and manage the purchased state stockpile.
- Those that reported cost estimates ranged from about “\$8,000 per year” to “\$183,998 annually ...until the product expires.” One state reported, “The estimated storage cost for 2.3 million courses is \$145,000 per year.” Many reported that they were in the process of determining storage management costs. Ultimately, costs are dependent on the quantity purchased, and many states are still in the process of determining how many antivirals they are going to purchase.
- States have indicated a critical need for resolution of storage, rotation, and shelf-life extension strategies.

